Maria Letizia Bacchi Reggiani

Maria Letizia Bacchi Reggiani

Auto-generated profile, based on publicly available information

Maria Letizia Bacchi Reggiani

Division of Cardiology, University of Bologna, Bologna, Italy

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2005 in JACC
Verified
Journal Article
Closed access
EPEnrica Perugini
Enrica Perugini
PGPier Luigi Guidalotti
Pier Luigi Guidalotti
FSFabrizio Salvi
Fabrizio Salvi
RCRobin M.T. Cooke
Robin M.T. Cooke
CPCinzia Pettinato
Cinzia Pettinato
CRClaudio Rapezzi
Claudio Rapezzi

29 September 2009 in Circulation
Verified
Journal Article
Closed access
CRClaudio Rapezzi
Claudio Rapezzi
GMGiampaolo Merlini
Giampaolo Merlini
CQCandida C. Quarta
Candida C. Quarta
LRLetizia Riva
Letizia Riva
SLSimone Longhi
Simone Longhi
Stefano PerliniStefano Perlini
Stefano Perlini
Background— Most studies of amyloidotic cardiomyopathy consider as a single entity the 3 main systemic cardiac amyloidoses: acquired monoclonal immunoglobulin light-chain (AL); hereditary, mutated transthyretin-related (ATTRm); and wild-type transthyretin-related (ATTRwt). In this study, we compared the diagnostic/clinical profiles of these 3 types of systemic cardiac amyloidosis. Methods and Results— We conducted a longitudinal study of 233 patients with clear-cut diagnosis by type of cardiac amyloidosis (AL, n=157; ATTRm, n=61; ATTRwt, n=15) at 2 large Italian centers providing coordinated amyloidosis diagnosis/management facilities since 1990. Average age at diagnosis was higher in AL than in ATTRm patients; all ATTRwt patients except 1 were elderly men. At diagnosis, mean left ventricular wall thickness was higher in ATTRwt than in ATTRm and AL. Left ventricular ejection fraction was moderately depressed in ATTRwt but not in AL or ATTRm. ATTRm patients less often displayed low QRS voltage (25% versus 60% in AL; P <0.0001) or low voltage-to-mass ratio (1.1±0.5 versus 0.9±0.5; P <0.0001). AL patients appeared to have greater hemodynamic impairment. On multivariate analysis, ATTRm was a strongly favorable predictor of survival, and ATTRwt predicted freedom from major cardiac events. Conclusions— AL, ATTRm, and ATTRwt should be considered 3 different cardiac diseases, probably characterized by different pathophysiological substrates and courses. Awareness of the diversity underlying the cardiac amyloidosis label is important on several levels, ranging from disease classification to diagnosis and clinical management.

27 September 2008 in European Heart Journal
Verified
Journal Article
Open access
PDF file
NGNazzareno Galiè
Nazzareno Galiè
AMAlessandra Manes
Alessandra Manes
LNLuca Negro
Luca Negro
MPMassimiliano Palazzini
Massimiliano Palazzini
MBMaria Letizia Bacchi-Reggiani
Maria Letizia Bacchi-Reggiani
ABAngelo Branzi
Angelo Branzi
There is no cure for pulmonary arterial hypertension, but current approved treatment options include prostanoids, endothelin-receptor antagonists, and phosphodiesterase type-5 inhibitors. The effect on survival of these compounds has not been appropriately assessed in individual trials because of small sample size and short duration. We performed a meta-analysis of all randomized controlled trials with drugs published in this condition. Trials were searched in the Medline database from January 1990 to October 2008. The primary analysis included only studies with a placebo comparator arm, the sensitivity analysis also included studies comparing two active treatment arms. The main outcome measure was all-cause mortality. Twenty-one trials were included in the primary analysis (3140 patients) and two additional studies (59 patients) were included in the sensitivity analysis. Average duration of the trials was 14.3 weeks. All-cause mortality rate in the control group was 3.8%. Active treatments were associated with a reduction in mortality of 43% (RR 0.57; 95% CI 0.35–0.92; P = 0.023); the sensitivity analysis confirmed a reduction in mortality of 38% (RR 0.62; 95% CI 0.39–1.00; P = 0.048). The results of this meta-analysis suggest an improvement of survival in the patients treated with the targeted therapies approved for pulmonary arterial hypertension.

1 September 2012 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
ACAntonio Colecchia
Antonio Colecchia
LMLucia Montrone
Lucia Montrone
ESEleonora Scaioli
Eleonora Scaioli
MBMaria Letizia Bacchi–Reggiani
Maria Letizia Bacchi–Reggiani
ACAgostino Colli
Agostino Colli
DFDavide Festi
Davide Festi

1 June 2015 in JACC
Verified
Journal Article
Closed access
TPTullio Palmerini
Tullio Palmerini
UBUmberto Benedetto
Umberto Benedetto
Giuseppe Biondi-ZoccaiGiuseppe Biondi-Zoccai
Giuseppe Biondi-Zoccai
DRDiego Della Riva
Diego Della Riva
LBLetizia Bacchi-Reggiani
Letizia Bacchi-Reggiani
GSGregg W. Stone
Gregg W. Stone

1 June 2015 in The Lancet
Verified
Journal Article
Closed access
TPTullio Palmerini
Tullio Palmerini
UBUmberto Benedetto
Umberto Benedetto
LBLetizia Bacchi-Reggiani
Letizia Bacchi-Reggiani
DRDiego Della Riva
Diego Della Riva
Giuseppe Biondi-ZoccaiGiuseppe Biondi-Zoccai
Giuseppe Biondi-Zoccai
GSGregg W Stone
Gregg W Stone